Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.99 -0.45 (-0.93%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

10 Monster Stocks to Hold for the Next 10 Years ↗

July 08, 2025

Each of these 10 businesses offers a market-leading product or service within an industry that's set to explode.

Via The Motley Fool

Cathie Wood-Led Ark Launches Buffer ETFs For Its Flagship ARKK, Analyst Says It's Like Diet Soda — 50% Loss Protection, But There's A Catch ↗

July 08, 2025

Cathie Wood's Ark Investment Management has filed plans to launch four new exchange-traded funds designed to offer downside protection for investors in its flagship ARK Innovation ETF (BATS: ARKK),...

Via Benzinga

Topics ETFs

2 Beaten-Down Stocks With Massive Upside Potential ↗

July 03, 2025

Via The Motley Fool

2 Growth Stocks to Buy Hand Over Fist in July ↗

July 02, 2025

These companies are poised to produce fireworks for your portfolio over the coming years.

Via The Motley Fool

44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy ↗

June 27, 2025

The 2025 TIME 100 Most Influential Companies list includes over 40 companies that investors can buy stock in.

Via Benzinga

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts ↗

June 21, 2025

Via The Motley Fool

FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering ↗

June 20, 2025

FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Via Investor's Business Daily

Topics Government

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday ↗

June 17, 2025

Via Benzinga

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Via Investor's Business Daily

Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It ↗

June 09, 2025

Cathie Wood is bullish on biotech companies using gene sequencing, AI, and CRISPR tech to cure previously untreatable diseases.

Via Benzinga

Topics Artificial Intelligence

The Best Stocks to Invest $1,000 in Right Now ↗

June 03, 2025

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to bear more fruit.

Via The Motley Fool

Topics Government World Trade

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip ↗

June 02, 2025

Via The Motley Fool

Topics Economy

5 Monster Stocks to Hold for the Next 10 Years ↗

May 20, 2025

These companies are just starting to realize the potential in up-and-coming fields, like AI and gene editing.

Via The Motley Fool

Topics Artificial Intelligence

CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy? ↗

May 20, 2025

Via The Motley Fool

Prediction: This Beaten-Down Stock Could Double in The Next 5 Years ↗

May 18, 2025

Via The Motley Fool

CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

May 16, 2025

CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders

Via MarketBeat

Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? ↗

May 14, 2025

Via The Motley Fool

2 Biotech Stocks That Are Screaming Buys in May ↗

May 13, 2025

Via The Motley Fool

Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? ↗

May 12, 2025

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.

Via The Motley Fool

3 Monster Stocks to Hold for the Next 10 Years ↗

May 10, 2025

The planets are lining up for these three stocks' underlying companies.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

May 08, 2025

In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs.

Via The Motley Fool

Topics Artificial Intelligence World Trade

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst ↗

May 07, 2025

CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.

Via Benzinga

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results ↗

May 07, 2025

Via Benzinga

Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 07, 2025

Via Benzinga

Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks ↗

May 06, 2025

The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.

Via Investor's Business Daily

Topics Government Intellectual Property

Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant ↗

April 30, 2025

On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.